Assessment of Grazax® Treatment Compliance

Phase 3

Completed

• Conditions: Allergy

• Registration Number: NCT00293046
• Lead Sponsor: ALK-Abelló A/S

Brief Summary

This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).

Detailed Description

Not available

Study Timeline

• Study Start: 2006-02
• Study First Submitted: 2006-02-16
• Study First Submitted QC: 2006-02-16
• Study First Posted: 2006-02-17
• Primary Completion: 2006-09
• Study Completion: 2007-10
• Status Verified: 2008-09
• Last Update Submitted: 2008-09-29
• Last Update Posted: 2008-09-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Grass pollen induced rhinoconjunctivitis
• Males and females, 18-65 years of age
• Positive skin prick test

Exclusion Criteria

• Previous treatment with grass pollen allergen

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Assessment of treatment compliance by recording of drug accountability

Secondary Outcome Measures

Name	Time	Method
Recording of adverse events

Trial Locations

Locations (1)

Allgergie - Ambulatorium Rennweg; 🇦🇹 Wien, Austria